We are delighted to announce that the Ministry of Health of the Republic of Slovenia (Ministrstvo za zdravje) has officially joined the funding organisations participating in the first Joint Transnational Call for Proposals on Rare Disease Therapies. This initiative is part of ERDERA’s ongoing commitment to advancing cutting-edge research in this critical area.
This collaboration represents a major milestone in strengthening international cooperation to address rare diseases through innovative therapeutic approaches. It also highlights an important advancement in promoting greater inclusion and participation of countries that have been underrepresented in funding calls, paving the way for more equitable research opportunities.
Updated call documents now available
We are pleased to announce that the updated documents for the JTC 2025 are now accessible on our website. These documents provide detailed information on eligibility, application guidelines, and evaluation criteria, ensuring a smooth and informed proposal submission process.
Key updates (as of 16 January 2025):
- Call text: addition of Ministry of Health of the Republic of Slovenia (SI MoH), Slovenia, to funding organisations participating in the call and to underrepresented countries list.
- Guidelines: changes in national guidelines for FCT, CIHR, RCN, BMBF, multinational PAO funding; addition of national guidelines for SI MoH, Slovenia.
- Pre-proposal submission preview: removal of budget justification entries.
- FAQ: additional Q&A.
For further details, access the updated call documents here.
Application timeline
The JTC 2025 will follow a two-stage submission process:
- 13 February 2025: Pre-proposal submission deadline.
- 9 July 2025: Full proposals submission deadline. Funding decisions are expected by December 2025.
Contact and stay updated
For more information, contact the Joint Call Secretariat at SelteneErkrankungen@dlr.de or reach out to the relevant national contact point.
Stay informed with the latest updates from ERDERA by regularly visiting our website, subscribing to our newsletter, and following us on social media.
